Biomarkers of Insufficient Sleep & Sleepiness

Status Completed

Clinical Trial Summary

Sleep and wakefulness disorders impact 50 to 70 million Americans and insufficient sleep is epidemic with over 50% of Americans reporting less than 7 hours of sleep per night. Health problems associated with insufficient sleep include inflammation, depression and anxiety, diabetes, stress, drug abuse, poor quality of life, obesity, and fatigue related accidents on the job/while driving. While the contribution of sleep to overall health, well-being, and public safety is recognized, no established clinical biomarkers of sleep deficiency exist. Such biomarkers would have utility as road-side biomarkers of sleepiness (e.g., drowsy driving), monitoring on the job fatigue/fitness for duty (e.g., transportation, military ops health care), monitoring sleep health, as well as for clinical diagnostics and measures of clinical treatment outcomes. Thus, investigators designed a controlled laboratory insufficient sleep protocol utilizing metabolomics to identify biomarkers of insufficient sleep. Investigators propose to identify changes in metabolites that consistently occur during insufficient sleep. As an exploratory outcome investigators will examine associated changes in metabolites and cognitive performance during insufficient sleep.

Clinical Trial Description

Impaired sleep affects millions of people each year representing an important public health issue. This project will utilize metabolomics approaches to identify biomarkers in the blood that respond consistently to insufficient sleep. The overall goal of this project is to use a discovery and targeted approach to identify specific small molecules in plasma as candidate biomarkers of insufficient sleep. Investigators will conduct a controlled in-laboratory insufficient sleep protocol where participants receive 2 days of 5 hour sleep opportunities per night on 2 separate occasions. Plasma will be collected for metabolomics analyses every 2 hours (across 24 hours) during scheduled wakefulness at baseline and during insufficient sleep. Participants will complete the insufficient sleep protocol twice, separated by 23 days of sufficient sleep, to identify which plasma metabolites consistently change during insufficient sleep. Investigators anticipate these findings will be the first step in establishing validated biomarkers of impaired sleep that will advance our understanding, assessment and management of health consequences and symptoms associated with insufficient sleep. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03130803
Study type	Interventional
Source	University of Colorado, Boulder
Contact
Status	Completed
Phase	N/A
Start date	January 19, 2017
Completion date	February 22, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05956886` - Sleep Chatbot Intervention for Emerging Black/African American Adults	N/A
Completed	`NCT02996864` - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II	N/A
Completed	`NCT03129204` - Sensation Awareness Focused Training for Spouses	N/A
Withdrawn	`NCT04049682` - Start Times and Restful Sleep
Completed	`NCT03182413` - Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation	Phase 1
Not yet recruiting	`NCT01930279` - Effect of Partial Sleep Deprivation on Immunological System in Peripheral Blood	N/A
Completed	`NCT01989741` - Effect of Sleep Restriction on Decision Making and Inflammation	N/A
Completed	`NCT00228215` - Tips for Infant and Parent Sleep (TIPS)	N/A
Completed	`NCT00123214` - A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation	N/A
Completed	`NCT00079664` - Comparing Tai Chi Training to a Low-Stress Physical Activity to Enhance Sleep in Older Adults	Phase 1
Completed	`NCT04179838` - Olfactory Contributions to Sleep-dependent Food Craving	N/A
Not yet recruiting	`NCT05513339` - Effect of Sleep Deprivation on Cognitive Function Among Cardiology Fellows
Recruiting	`NCT05026541` - Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators	N/A
Withdrawn	`NCT04096261` - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting	`NCT06017882` - Combined Effects of Acute Sleep Restriction and Moderate Acceleration (+Gz) on Physiological and Behavioral Responses to High Mental Workload
Completed	`NCT00179322` - Effects of Sleep Deprivation and Recovery on Cognitive Functions
Recruiting	`NCT06399939` - The Function of Biphasic Sleep in Infants	N/A
Not yet recruiting	`NCT06027047` - Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Completed	`NCT05162105` - Quick Returns - Sleep, Cognitive Functions and Individual Differences	N/A
Completed	`NCT03981770` - Characterisation of Gut Microbiota, Bispectral Index Data and Plasma Kynurenine in Patients Undergoing Thyroid Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Biomarkers of Insufficient Sleep and Sleepiness

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms